These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17022826)

  • 1. Highly active antiretroviral therapy and hospital readmission: comparison of a matched cohort.
    Nosyk B; Sun H; Li X; Palepu A; Anis AH
    BMC Infect Dis; 2006 Oct; 6():146. PubMed ID: 17022826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting hospitalization among HIV-infected antiretroviral naïve patients starting HAART: determining clinical markers and exploring social pathways.
    Fielden SJ; Rusch ML; Levy AR; Yip B; Wood E; Harrigan RP; Goldstone I; Guillemi S; Montaner JS; Hogg RS
    AIDS Care; 2008 Mar; 20(3):297-303. PubMed ID: 18351476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of early hospital readmission in HIV-infected patients with pneumonia.
    Palepu A; Sun H; Kuyper L; Schechter MT; O'Shaughnessy MV; Anis AH
    J Gen Intern Med; 2003 Apr; 18(4):242-7. PubMed ID: 12709090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
    Stoll M; Claes C; Schulte E; Graf von der Schulenburg JM; Schmidt RE
    Eur J Med Res; 2002 Nov; 7(11):463-71. PubMed ID: 12568973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and benefits of HAART for patients with HIV in a public hospital in Mexico.
    Aracena-Genao B; Navarro JO; Lamadrid-Figueroa H; Forsythe S; Trejo-Valdivia B
    AIDS; 2008 Jul; 22 Suppl 1():S141-8. PubMed ID: 18664946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART.
    Fielden SJ; Rusch ML; Yip B; Wood E; Shannon K; Levy AR; Montaner JS; Hogg RS
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(5):238-44. PubMed ID: 18812590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.
    Hubben GA; Bishai D; Pechlivanoglou P; Cattelan AM; Grisetti R; Facchin C; Compostella FA; Bos JM; Postma MJ; Tramarin A
    AIDS Care; 2008 Apr; 20(4):449-55. PubMed ID: 18449822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality.
    Wyatt CM; Arons RR; Klotman PE; Klotman ME
    AIDS; 2006 Feb; 20(4):561-5. PubMed ID: 16470120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment?
    Farnham PG
    Appl Health Econ Health Policy; 2010; 8(2):75-88. PubMed ID: 20175587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.